Abstract: A magnetic resonance guided laser ablation treatment system, including: an optical fiber cooling assembly (400), accommodating and cooling an ablation optical fiber (5); a laser ablation apparatus (200), including a laser generator and a cooling device; a stereotactic driving system (300), accommodating and controlling the position and angle of rotation of the ablation optical fiber (5); and a workstation (100), configured to control the movement of a stereotactic driving system, and generate and display ablation information of the target region during the workflow of the magnetic resonance guided laser ablation treatment system by using the magnetic resonance temperature imaging technology.

Abstract: A display substrate and a display device are provided. The display substrate includes a base substrate, at least one group of contact pads, a plurality of first light-emitting elements, a plurality of first pixel driving circuits, a plurality of connecting traces, a plurality of data lines and a plurality of leads. The display area includes a first display area and a second display area; the first light-emitting elements are located in the first display area; the first pixel driving circuits are located in the second display area; the leads are located in the first display area and the peripheral area, and connect the data lines and the at least one group of contact pads; orthographic projections of the first light-emitting elements on a substrate surface of the base substrate are at least partly overlapped with orthographic projections of the leads on the substrate surface of the base substrate.

Abstract: Prodrugs that target the low-density lipoprotein receptor (LDLR) and that comprise acid and/or enzyme cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate bonds are described. Also described are core-shell nanoparticles comprising metal-organic framework cores or nanoscale metal bisphosphate coordination polymer cores, and lipid coating layers containing the prodrugs. The nanoparticle core can optionally contain one or more hydrophilic chemotherapeutic agents. The prodrugs and nanoparticles can be used in methods of treating cancer. For instance, the presently disclosed nanoparticles can be used for the co-delivery of multiple chemotherapeutic agents in methods providing increased accumulation of chemotherapeutic agents to a tumor compared to delivery of mixtures of free chemotherapeutic agents.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: The disclosure provides a display method. The method includes: presenting a first partial image of a current display frame of a media object on a refreshed user interface in response to a user input for enlarging the media object for display; where the refreshed user interface further includes a thumbnail show window for presenting a position of the first partial image of the current display frame in the current display frame.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

Abstract: The disclosure provides a display method. The method includes: presenting a first partial image of a current display frame of a media object on a refreshed user interface in response to a user input for enlarging the media object for display; where the refreshed user interface further includes a thumbnail show window for presenting a position of the first partial image of the current display frame in the current display frame.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.